|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,793.50 INR | -0.76% |
|
-0.65% | -4.92% |
| 12-12 | Indian Stocks Extend Gains on Friday as Global Sentiment Improves After US Rate Cut | MT |
| 12-12 | Ozempic launches in India at $24 a week as Novo targets booming diabetes market | RE |
| Capitalization | 4,303B 47.51B 40.47B 37.81B 35.57B 65.49B 71.55B 441B 171B 2,028B 178B 175B 7,401B | P/E ratio 2026 * |
38.5x | P/E ratio 2027 * | 32.3x |
|---|---|---|---|---|---|
| Enterprise value | 4,086B 45.12B 38.43B 35.9B 33.78B 62.19B 67.94B 419B 163B 1,926B 169B 166B 7,027B | EV / Sales 2026 * |
7.12x | EV / Sales 2027 * | 6.3x |
| Free-Float |
44.9% | Yield 2026 * |
0.81% | Yield 2027 * | 0.92% |
Last Transcript: Sun Pharmaceutical Industries Ltd.
| 1 day | -0.76% | ||
| 1 week | -0.65% | ||
| Current month | -2.08% | ||
| 1 month | +3.54% | ||
| 3 months | +10.94% | ||
| 6 months | +6.29% | ||
| Current year | -4.92% |
| 1 week | 1,767.9 |  | 1,811.8 |
| 1 month | 1,734.7 | | 1,849 |
| Current year | 1,548 | | 1,896 |
| 1 year | 1,548 | | 1,910 |
| 3 years | 922.45 | | 1,960.35 |
| 5 years | 539.7 | | 1,960.35 |
| 10 years | 312 | | 1,960.35 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Chief Executive Officer | 58 | 31/08/2025 | |
| Director of Finance/CFO | 57 | 30/06/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 69 | - | |
| Director/Board Member | 73 | 24/05/2018 | |
| Director/Board Member | 70 | 20/05/2021 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.76% | -0.65% | -0.66% | +81.64% | 47.51B | |
| +0.13% | +1.65% | +5.26% | +104.17% | 31.57B | |
| -2.51% | -0.28% | +54.43% | - | 31.14B | |
| +0.34% | -0.22% | +4.98% | +38.35% | 13.53B | |
| +0.72% | -0.25% | -4.85% | +128.94% | 10.32B | |
| -0.83% | -2.98% | +71.74% | +78.37% | 9.28B | |
| 0.00% | -1.24% | +42.50% | +111.78% | 7.13B | |
| -.--% | +0.14% | - | - | 6.79B | |
| -0.07% | +3.52% | +27.09% | -36.40% | 6.57B | |
| +0.97% | +0.35% | +28.66% | +364.65% | 6.15B | |
| Average | -0.20% | -0.02% | +25.46% | +108.94% | 17B | |
| Weighted average by Cap. | -0.59% | -0.03% | +19.42% | +95.00% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 574B 6.33B 5.4B 5.04B 4.74B 8.73B 9.54B 58.84B 22.82B 270B 23.77B 23.27B 987B | 634B 7B 5.96B 5.57B 5.24B 9.65B 10.54B 65.02B 25.22B 299B 26.27B 25.71B 1,090B |
| Net income | 112B 1.24B 1.05B 983M 925M 1.7B 1.86B 11.47B 4.45B 52.73B 4.63B 4.54B 192B | 134B 1.48B 1.26B 1.17B 1.1B 2.03B 2.22B 13.7B 5.31B 62.98B 5.54B 5.42B 230B |
| Net Debt | -217B -2.39B -2.04B -1.91B -1.79B -3.3B -3.61B -22.25B -8.63B -102B -8.99B -8.8B -373B | -307B -3.39B -2.89B -2.7B -2.54B -4.68B -5.11B -31.51B -12.22B -145B -12.73B -12.46B -528B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/12/25 | 1,793.50 ₹ | -0.76% | 1,442,309 |
| 11/12/25 | 1,807.20 ₹ | +1.22% | 1,280,916 |
| 10/12/25 | 1,785.50 ₹ | +0.53% | 2,321,746 |
| 09/12/25 | 1,776.00 ₹ | -1.12% | 2,401,728 |
| 08/12/25 | 1,796.20 ₹ | -0.50% | 2,410,074 |
Delayed Quote NSE India S.E., December 12, 2025 at 11:49 am
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- SUNPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition